<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi>, a thiazolidinedione, improves insulin sensitivity and thus reduces blood <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical trials have suggested potential cardiovascular outcome benefits in association with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>; however, safety concerns are mounting, with recent data suggesting a link between <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and an increased risk of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>There is thus a growing focus on the risk-benefit profile of this agent and hence its potential role in the blood <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering treatment algorithm for people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>There are clear potential outcome benefits associated with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In this review, the authors focus on putting the true risk-benefit profile of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> into context based on critical appraisal of the currently available evidence </plain></SENT>
</text></document>